

Yujin Hoshida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2121897/publications.pdf>

Version: 2024-02-01

184
papers

18,957
citations

16451

64
h-index

12597

132
g-index

187
all docs

187
docs citations

187
times ranked

26672
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1091-1093.e3.	4.4	15
2	Plasma-Signature-Model for End-Stage Liver Disease Score to Predict Survival in Severe Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 651-657.	4.4	3
3	A Blood-Based Prognostic Liver Secretome Signature Predicts Long-term Risk of Hepatic Decompensation in Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1188-e1191.	4.4	6
4	Role of Hepatocyte-Derived Osteopontin in Liver Carcinogenesis. <i>Hepatology Communications</i> , 2022, 6, 692-709.	4.3	6
5	Peroxidasin Deficiency Re-programs Macrophages Toward Pro-fibrosis Function and Promotes Collagen Resolution in Liver. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1483-1509.	4.5	9
6	miR-579-3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3-Kinase-Protein Kinase B Pathway in Chronically Inflamed Liver. <i>Hepatology Communications</i> , 2022, 6, 1467-1481.	4.3	8
7	Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease. <i>Hepatology International</i> , 2022, 16, 509-522.	4.2	16
8	HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 128-139.	3.7	139
9	Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts. <i>Advances in Cancer Research</i> , 2022, , .	5.0	0
10	Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	33
11	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. <i>Gastroenterology</i> , 2022, 162, 1210-1225.	1.3	17
12	Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	40
13	Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature. <i>Hepatology Communications</i> , 2022, 6, 2581-2593.	4.3	12
14	Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. <i>JCI Insight</i> , 2022, 7, .	5.0	4
15	Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. <i>Gut</i> , 2021, 70, 157-169.	12.1	57
16	Transcriptome-Guided Design of Physiological Multilineage Liver Organoids. <i>Trends in Genetics</i> , 2021, 37, 403-404.	6.7	1
17	High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	2.3	8
18	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2021, 160, 2572-2584.	1.3	91

#	ARTICLE	IF	CITATIONS
19	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. <i>Med</i> , 2021, 2, 836-850.e10.	4.4	31
20	N-Glycosylation Patterns Correlate with Hepatocellular Carcinoma Genetic Subtypes. <i>Molecular Cancer Research</i> , 2021, 19, 1868-1877.	3.4	21
21	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. <i>Nature Communications</i> , 2021, 12, 5525.	12.8	21
22	Gene signature and MELD score and alcohol relapse determine long-term prognosis of patients with severe alcoholic hepatitis. <i>Liver International</i> , 2020, 40, 565-570.	3.9	12
23	Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. <i>Journal of Clinical Medicine</i> , 2020, 9, 3817.	2.4	27
24	Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. <i>Journal of Clinical Medicine</i> , 2020, 9, 3843.	2.4	10
25	Viral Exposure Signature Associated with Liver Cancer Risk. <i>Trends in Molecular Medicine</i> , 2020, 26, 711-713.	6.7	2
26	A human liver cell-based system modeling a clinical prognostic liver signature combined with single cell RNA-seq for discovery of novel liver disease therapeutics. <i>Journal of Hepatology</i> , 2020, 73, S28-S29.	3.7	0
27	A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor. <i>Nature Communications</i> , 2020, 11, 2707.	12.8	11
28	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 2522-2534.	3.9	20
29	Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters. <i>Pharmacogenomics</i> , 2020, 21, 575-586.	1.3	5
30	Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. <i>Hepatology</i> , 2020, 72, 1654-1665.	7.3	93
31	MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. <i>European Radiology</i> , 2020, 30, 3759-3769.	4.5	97
32	Restricted immunological and cellular pathways are shared by murine models of chronic alcohol consumption. <i>Scientific Reports</i> , 2020, 10, 2451.	3.3	8
33	Mice With Increased Numbers of Polyploid Hepatocytes Maintain Regenerative Capacity But Develop Fewer Hepatocellular Carcinomas Following Chronic Liver Injury. <i>Gastroenterology</i> , 2020, 158, 1698-1712.e14.	1.3	55
34	Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. <i>Hepatology Research</i> , 2020, 50, 817-830.	3.4	13
35	Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma. <i>Cancer Prevention Research</i> , 2020, 13, 497-508.	1.5	24
36	Somatic mutation landscape reveals differential variability of cell-of-origin for primary liver cancer. <i>Heliyon</i> , 2020, 6, e03350.	3.2	7

#	ARTICLE	IF	CITATIONS
37	Steatohepatic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1406-1412.	3.7	15
38	Current Status of the Use of Statins and Aspirin in the Chemoprevention of Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2020, 16, 319-321.	0.1	0
39	GIGSEA: genotype imputed gene set enrichment analysis using GWAS summary level data. <i>Bioinformatics</i> , 2019, 35, 160-163.	4.1	11
40	Use of big data in drug development for precision medicine: an update. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 189-200.	0.7	51
41	Risk Factors of Hepatocellular Carcinoma for Precision Personalized Care. <i>Molecular and Translational Medicine</i> , 2019, , 3-25.	0.4	6
42	Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2019, 9, 10663.	3.3	57
43	Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus-Infected Cells and Liver to Identify Pathways Associated With Disease Development. <i>Gastroenterology</i> , 2019, 157, 537-551.e9.	1.3	71
44	MPIC: Molecular Prognostic Indicators in Cirrhosis Database for Clinical Context-Specific in Silico Prognostic Biomarker Validation. <i>Frontiers in Genetics</i> , 2019, 10, 830.	2.3	1
45	Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. <i>Experimental Hematology</i> , 2019, 79, 16-25.e3.	0.4	8
46	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 4326-4330.	0.9	99
47	Dose and Duration of Aspirin Use to Reduce Incident Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 2216-2217.	7.3	7
48	Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma. <i>Viruses</i> , 2019, 11, 441.	3.3	5
49	HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. <i>Gastroenterology</i> , 2019, 156, 2313-2329.e7.	1.3	184
50	Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis. <i>Seminars in Liver Disease</i> , 2019, 39, 153-162.	3.6	5
51	Aspirin: Does it Have a Role for Chemoprevention of Hepatocellular Carcinoma?. <i>Gastroenterology</i> , 2019, 156, 1530-1531.	1.3	2
52	Generic chemoprevention of hepatocellular carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2019, 1440, 23-35.	3.8	16
53	Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. <i>Cell Metabolism</i> , 2019, 29, 174-182.e5.	16.2	246
54	High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. <i>Translational Oncology</i> , 2019, 12, 256-268.	3.7	28

#	ARTICLE	IF	CITATIONS
55	Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 101-111.	1.7	30
56	CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. <i>Gut</i> , 2018, 67, 1493-1504.	12.1	131
57	Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis. <i>Gastroenterology</i> , 2018, 154, 965-975.	1.3	41
58	In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment. <i>Experimental and Molecular Medicine</i> , 2018, 50, e419-e419.	7.7	37
59	A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. <i>Journal of Hepatology</i> , 2018, 69, 385-395.	3.7	330
60	miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. <i>Gut</i> , 2018, 67, 953-962.	12.1	59
61	Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. <i>Journal of Hepatology</i> , 2018, 68, 526-549.	3.7	506
62	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	7.3	70
63	Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 317-325.	3.3	12
64	Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. <i>Nature Communications</i> , 2018, 9, 4962.	12.8	111
65	Molecular heterogeneity in hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2018, 5, HEP10.	4.2	18
66	Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2018, 9, 2.	2.3	32
67	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. <i>Cell</i> , 2018, 174, 1200-1215.e20.	28.9	96
68	The Hypomorphic Gata1 ^{low} Mutation Induces Fibrosis in Multiple Organs. <i>Blood</i> , 2018, 132, 3059-3059.	1.4	0
69	Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. <i>Gut</i> , 2017, 66, 530-540.	12.1	161
70	Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. <i>Scientific Reports</i> , 2017, 7, 42563.	3.3	29
71	Hepatic stellate cells as key target in liver fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2017, 121, 27-42.	13.7	943
72	Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. <i>European Radiology</i> , 2017, 27, 4472-4481.	4.5	40

#	ARTICLE	IF	CITATIONS
73	The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1311827.	0.7	22
74	Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53. <i>Clinical Cancer Research</i> , 2017, 23, 5446-5459.	7.0	14
75	Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. <i>Scientific Reports</i> , 2017, 7, 2452.	3.3	70
76	Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature. <i>Hepatology</i> , 2017, 66, 1344-1346.	7.3	28
77	Tailored Algorithms for Hepatocellular Carcinoma Surveillance: Is One-Size-Fits-All Strategy Outdated?. <i>Current Hepatology Reports</i> , 2017, 16, 64-71.	0.9	17
78	Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. <i>BMC Medicine</i> , 2017, 15, 52.	5.5	116
79	Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. <i>Gut</i> , 2017, 66, 1286-1296.	12.1	198
80	Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury. <i>Scientific Reports</i> , 2017, 7, 8119.	3.3	29
81	Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases. <i>Experimental and Molecular Medicine</i> , 2017, 49, e396-e396.	7.7	61
82	Loss of DNA methylation in zebrafish embryos activates retrotransposons to trigger antiviral signaling. <i>Development (Cambridge)</i> , 2017, 144, 2925-2939.	2.5	53
83	Cost-Effectiveness of Risk Score–Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e101.	2.5	124
84	Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. <i>Gastroenterology</i> , 2017, 152, 53-67.e3.	1.3	61
85	The role of GATA2 in lethal prostate cancer aggressiveness. <i>Nature Reviews Urology</i> , 2017, 14, 38-48.	3.8	71
86	MPI depletion enhances O-GlcNAcylation of p53 and suppresses the Warburg effect. <i>ELife</i> , 2017, 6, .	6.0	30
87	Comparative Epigenomic Profiling of the DNA Methylome in Mouse and Zebrafish Uncovers High Interspecies Divergence. <i>Frontiers in Genetics</i> , 2016, 7, 110.	2.3	42
88	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016, 30, 879-890.	16.8	172
89	The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy. <i>Scientific Reports</i> , 2016, 6, 39342.	3.3	77
90	Novel substituted aminothiazoles as potent and selective anti-hepatocellular carcinoma agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5819-5824.	2.2	6

#	ARTICLE	IF	CITATIONS
91	Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. <i>Current Opinion in Virology</i> , 2016, 20, 99-105.	5.4	62
92	Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes. <i>Cell Reports</i> , 2016, 17, 1357-1368.	6.4	34
93	Use of big data in drug development for precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 245-253.	0.7	28
94	Interleukin-15 receptor α on hepatic stellate cells regulates hepatic fibrogenesis in mice. <i>Journal of Hepatology</i> , 2016, 65, 344-353.	3.7	30
95	A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. <i>Journal of Hepatology</i> , 2016, 65, 579-588.	3.7	371
96	Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition. <i>International Journal of Cancer</i> , 2016, 138, 1494-1505.	5.1	29
97	Clinicopathological indices to predict hepatocellular carcinoma molecular classification. <i>Liver International</i> , 2016, 36, 108-118.	3.9	93
98	Induction and contribution of beta platelet-derived growth factor signalling by hepatic stellate cells to liver regeneration after partial hepatectomy in mice. <i>Liver International</i> , 2016, 36, 874-882.	3.9	14
99	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. <i>Gut</i> , 2016, 65, 1754-1764.	12.1	108
100	Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases?. <i>Gastroenterology</i> , 2016, 150, 1710-1717.	1.3	13
101	The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. <i>Genes and Development</i> , 2016, 30, 786-797.	5.9	78
102	Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1619-1628.	4.4	47
103	Personalized management of hepatocellular carcinoma based on molecular information: Future prospects. <i>Clinical Liver Disease</i> , 2015, 5, 132-135.	2.1	4
104	Origin and interpretation of cancer transcriptome profiling: the essential role of the stroma in determining prognosis and drug resistance. <i>EMBO Molecular Medicine</i> , 2015, 7, 1385-1387.	6.9	6
105	Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine. <i>Oncotarget</i> , 2015, 6, 8339-8352.	1.8	43
106	Hepatitis C virus-induced hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 105.	8.9	127
107	Molecular prognostic prediction in liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 10262.	3.3	12
108	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. <i>Neuro-Oncology</i> , 2015, 17, 1486-1496.	1.2	39

#	ARTICLE	IF	CITATIONS
109	YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. <i>Cell Reports</i> , 2015, 10, 1692-1707.	6.4	213
110	Molecular classification of hepatocellular carcinoma: potential therapeutic implications. <i>Hepatic Oncology</i> , 2015, 2, 371-379.	4.2	95
111	A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer. <i>Cancer Cell</i> , 2015, 27, 223-239.	16.8	128
112	Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. <i>Nature Communications</i> , 2015, 6, 6087.	12.8	240
113	DNA methylation-based prognosis and epdrivers in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 1945-1956.	7.3	367
114	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 806-818.e10.	1.3	109
115	DNA hypomethylation induces a DNA replication-associated cell cycle arrest to block hepatic outgrowth in <i>uhrf1</i> mutant zebrafish embryos. <i>Development (Cambridge)</i> , 2015, 142, 510-21.	2.5	49
116	β 2-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis. <i>Journal of Hepatology</i> , 2015, 63, 141-147.	3.7	142
117	A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. <i>Journal of Hepatology</i> , 2015, 63, 1323-1333.	3.7	22
118	Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. <i>Journal of Hepatology</i> , 2015, 63, 1368-1377.	3.7	64
119	Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. <i>Nature Immunology</i> , 2015, 16, 1235-1244.	14.5	278
120	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. <i>Gut</i> , 2015, 64, 1296-1302.	12.1	70
121	Cancer biomarker discovery and validation. <i>Translational Cancer Research</i> , 2015, 4, 256-269.	1.0	354
122	Transcriptome Profiling of Archived Sectioned Formalin-Fixed Paraffin-Embedded (AS-FFPE) Tissue for Disease Classification. <i>PLoS ONE</i> , 2014, 9, e86961.	2.5	39
123	Survival analysis tools in genomics research. <i>Human Genomics</i> , 2014, 8, 21.	2.9	9
124	Prognostic gene signature profiles of hepatitis C-related early-stage liver cirrhosis. <i>Genomics Data</i> , 2014, 2, 361-362.	1.3	3
125	CXCR4 pathway associated with family history of melanoma. <i>Cancer Causes and Control</i> , 2014, 25, 125-132.	1.8	3
126	UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2014, 25, 196-209.	16.8	261

#	ARTICLE	IF	CITATIONS
127	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. <i>Hepatology</i> , 2014, 59, 1577-1590.	7.3	290
128	Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, S79-S90.	3.7	181
129	Host Genetics Predict Clinical Deterioration in HCV-Related Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e114747.	2.5	11
130	Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1024-1030.	1.3	195
131	Prognostic Gene Signatures for Hepatocellular Carcinoma: What Are We Measuring?. <i>Annals of Surgical Oncology</i> , 2013, 20, 3707-3708.	1.5	1
132	Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma. <i>Hepatology</i> , 2013, 58, 2207-2207.	7.3	12
133	Expression Profiling of Archival Tumors for Long-term Health Studies. <i>Clinical Cancer Research</i> , 2012, 18, 6136-6146.	7.0	32
134	Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. <i>Gut</i> , 2012, 61, 847-854.	12.1	518
135	Molecular epidemiology of hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012, 1, 177-179.	2.1	2
136	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 4997-5007.	7.0	251
137	Genomic risk of hepatitis C-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 729-730.	3.7	15
138	Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. <i>Journal of Hepatology</i> , 2012, 56, 1343-1350.	3.7	181
139	Gene Signatures in the Management of Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 473-485.	2.2	68
140	Prevention of Hepatocellular Carcinoma: Potential Targets, Experimental Models, and Clinical Challenges. <i>Current Cancer Drug Targets</i> , 2012, 12, 1129-1159.	1.6	39
141	Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. <i>Current Cancer Drug Targets</i> , 2012, 12, 1129-59.	1.6	55
142	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1501-1512.e2.	1.3	389
143	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , 2011, 43, 964-968.	21.4	270
144	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 55, 1325-1331.	3.7	133

#	ARTICLE	IF	CITATIONS
145	Depicting the role of TP53 in hepatocellular carcinoma progression. <i>Journal of Hepatology</i> , 2011, 55, 724-725.	3.7	54
146	SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. <i>Nature</i> , 2011, 470, 269-273.	27.8	462
147	Carcinogen-induced hepatic tumors in KLF6+/Δ mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. <i>Hepatology</i> , 2011, 54, 522-531.	7.3	39
148	mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2391-2396.	1.6	140
149	Inherited hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 725-734.	2.4	28
150	New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers. <i>Clinical Cancer Research</i> , 2010, 16, 4688-4694.	7.0	114
151	Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. <i>Seminars in Liver Disease</i> , 2010, 30, 035-051.	3.6	267
152	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. <i>Journal of Hepatology</i> , 2010, 52, 550-559.	3.7	211
153	Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment. <i>PLoS ONE</i> , 2010, 5, e15543.	2.5	249
154	Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2009, 69, 7385-7392.	0.9	978
155	Lin28 promotes transformation and is associated with advanced human malignancies. <i>Nature Genetics</i> , 2009, 41, 843-848.	21.4	742
156	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009, 51, 725-733.	3.7	206
157	Tumor-derived molecular information and outcome in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2009, 51, 595-596.	3.7	2
158	Risk of recurrence in hepatitis B-related hepatocellular carcinoma: Impact of viral load in late recurrence. <i>Journal of Hepatology</i> , 2009, 51, 842-844.	3.7	33
159	Molecular profiling to predict hepatocellular carcinoma outcome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 101-103.	3.0	37
160	Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 6779-6788.	0.9	589
161	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 1995-2004.	27.0	1,148
162	Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 815-825.	6.3	286

#	ARTICLE	IF	CITATIONS
163	Gene Expression Changes in an Animal Melanoma Model Correlate with Aggressiveness of Human Melanoma Metastases. <i>Molecular Cancer Research</i> , 2008, 6, 760-769.	3.4	216
164	Changes in hepatic functional reserve after percutaneous tumor ablation for hepatocellular carcinoma: long-term follow up for 227 consecutive patients with a single lesion. <i>Hepatology International</i> , 2007, 1, 295-301.	4.2	13
165	Subclass Mapping: Identifying Common Subtypes in Independent Disease Data Sets. <i>PLoS ONE</i> , 2007, 2, e1195.	2.5	437
166	Gene expressions associated with chemosensitivity in human hepatoma cells. <i>Hepato-Gastroenterology</i> , 2007, 54, 489-92.	0.5	10
167	Topological and Functional Discovery in a Gene Coexpression Meta-Network of Gastric Cancer. <i>Cancer Research</i> , 2006, 66, 232-241.	0.9	83
168	Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization. <i>Oncogene</i> , 2005, 24, 7105-7113.	5.9	90
169	Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. <i>Hepatology</i> , 2005, 42, 846-853.	7.3	57
170	Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. <i>Proteomics</i> , 2005, 5, 4287-4295.	2.2	55
171	Vitamin K2 binds 17 β -hydroxysteroid dehydrogenase 4 and modulates estrogen metabolism. <i>Life Sciences</i> , 2005, 76, 2473-2482.	4.3	22
172	Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients. <i>World Journal of Gastroenterology</i> , 2005, 11, 1995.	3.3	43
173	Identifying genes with differential expression in gemcitabine-resistant pancreatic cancer cells using comprehensive transcriptome analysis. <i>Oncology Reports</i> , 2005, 14, 1263-7.	2.6	9
174	UDP-Glucuronosyltransferase 1A7 Genetic Polymorphisms Are Associated with Hepatocellular Carcinoma in Japanese Patients with Hepatitis C Virus Infection. <i>Clinical Cancer Research</i> , 2004, 10, 2441-2446.	7.0	63
175	Vitamin K ₂ inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. <i>Hepatology</i> , 2004, 40, 243-251.	7.3	124
176	A simple combination of serum type IV collagen and prothrombin time to diagnose cirrhosis in patients with chronic active hepatitis C. <i>Hepatology Research</i> , 2004, 30, 214-220.	3.4	14
177	Proteomic analysis of the TGF- β 2 signaling pathway in pancreatic carcinoma cells using stable RNA interference to silence Smad4 expression. <i>Biochemical and Biophysical Research Communications</i> , 2004, 318, 289-296.	2.1	33
178	Interleukin-1 β gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. <i>Hepatology</i> , 2003, 37, 65-71.	7.3	154
179	Relevance network between chemosensitivity and transcriptome in human hepatoma cells. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 199-205.	4.1	39
180	Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma. <i>Liver</i> , 2002, 22, 479-485.	0.1	11

#	ARTICLE	IF	CITATIONS
181	Hepatic volumetry to predict adverse events in percutaneous ablation of hepatocellular carcinoma. Hepato-Gastroenterology, 2002, 49, 451-5.	0.5	5
182	Difficulties in Conducting Controlled Trials in Radical Therapies for Nonadvanced Hepatocellular Carcinoma. Hepatology, 2000, 32, 877-881.	7.3	14
183	Aged Budd-Chiari syndrome attributed to chronic deep venous thrombosis with alcoholic liver cirrhosis. Journal of Gastroenterology, 1999, 34, 634-639.	5.1	0
184	Chronic liver disease in the extremely elderly of 80 years or more: clinical characteristics, prognosis and patient survival analysis. Journal of Hepatology, 1999, 31, 860-866.	3.7	42